FrancisWilliamPriceJr.MD

Clinical Trials

• Study of Endothelial Keratoplasty Outcomes Start of enrollment: 2008 Feb 01

  Completed

  Not Applicable

• Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients Start of enrollment: 2009 May 01

  Terminated

  Not Applicable

• Cross Linking for Treatment of Corneal Infection Start of enrollment: 2009 May 01

  Terminated

  Not Applicable

• Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia Start of enrollment: 2010 May 01

  Completed

  Phase 2

• Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus Start of enrollment: 2012 Jul 01

  Completed

  Phase 3

• Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty Start of enrollment: 2013 Mar 01

  Completed

  Phase 4

• Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects Start of enrollment: 2013 Oct 01

  Recruiting

  Not Applicable

• Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation Start of enrollment: 2014 May 01

  Completed

  Phase 3

• Study of Ataluren in Participants With Nonsense Mutation Aniridia Start of enrollment: 2016 Jan 31

  Completed

  Phase 2

• Effect of TrueTear Corneal Surface Imaging Start of enrollment: 2018 Aug 13

  Completed

  Not Applicable

• Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration Start of enrollment: 2019 Jul 22

  Terminated

  Phase 2, Phase 3

• Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections. Start of enrollment: 2019 Jul 03

  Withdrawn

  Phase 2, Phase 3

• Rhopressa for Corneal Edema Associated With Fuchs Dystrophy Start of enrollment: 2019 Aug 05

  Completed

  Phase 2, Phase 3

• Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Start of enrollment: 2022 Mar 14

  Recruiting

  Phase 2, Phase 3

  Roles: Contact

• Join now to see all